The efficacy and safety of alpha-1 blockers for benign prostatic hyperplasia: an overview of 15 systematic reviews

  title={The efficacy and safety of alpha-1 blockers for benign prostatic hyperplasia: an overview of 15 systematic reviews},
  author={Jinqiu Yuan and Ya-li Liu and Zuyao Yang and Xiwen Simon Qin and Kehu Yang and Chen Mao},
  journal={Current Medical Research and Opinion},
  pages={279 - 287}
Abstract Objective: A great number of clinical trials and systematic reviews have evaluated the efficacy and safety of α1 blockers for benign prostatic hyperplasia (BPH). We carried out an overview of reviews to provide an up-to-date summary of evidence regarding the efficacy and safety between different α1 blockers for BPH. Research design and methods: PubMed, EMBASE, the Cochrane Library, China National Knowledge Infrastructure, Chinese BioMedical Literature Database and VIP were searched for… 

Comparative Effectiveness and Safety of Monodrug Therapies for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia

Drug therapies for BPH are generally safe and well-tolerated, with no major difference regarding the overall safety profile, and doxazos in and terazosin appear to be the most effective agents.

General effect of low-dose tamsulosin (0.2 mg) as a first-line treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia: a systematic review and meta-analysis

It is clarified that low-dose tamsulosin has generally positive effect and safety in treatment of LUTS and could be a suitable option as an initial treatment, especially for patients with low body mass index, as is typical of Asian people.

Safety of Tamsulosin: A Systematic Review of Randomized Trials with a Focus on Women and Children

The overall safety profile in women and children seemed to be generally consistent with the profile in men, the indicated population, in an all-comers population treated with tamsulosin for various conditions/symptoms.

Is Tamsulosin 0.2 mg Effective and Safe as a First-Line Treatment Compared with Other Alpha Blockers?: A Meta-Analysis and a Moderator Focused Study

It is clarified that tamsulosin 0.2 mg has similar efficacy and fewer adverse events compared with other alpha-blockers as an initial treatment strategy for men with lower urinary tract symptoms.

Pharmacotherapy and herbal treatment of benign prostatic hyperplasia.

For patients with moderate to severe symptoms and a large prostate, combination therapy with α-blockers and 5-ARIs can further improve clinical efficacy of treatment.

Add-on Therapy With the α-Blockers Tamsulosin and Naftopidil Improves Voiding Function by Enhancing Neuronal Activity in Prostatic Hyperplasia Rats

Combination therapy of tamsULosin and naftopidil showed greater efficacy for the treatment of BPH than tamsulosin monotherapy or naftipidil monotherapy; therefore, combination therapy can be considered as a novel therapeutic method for BPH.

Effects of Roystonea Regia (D-004) and Saw Palmetto Lipid Extracts in Men with Symptomatic benign Prostatic Hyperplasia

D-004 (320 mg/day), a lipid extract of Roystonea regia fruits, reduced experimental prostate hyperplasia in rodents and the International Prostate Symptoms Score (IPSS) as effectively as SP in a pilot trial in men with BPH.

A review of antidepressant-induced urinary hesitancy: a focus on levomilnacipran ER including two case presentations(5633)

The longitudinal course of levomilnacipran-induced urinary hesitancy in 2 cases that were in a pivotal clinical trial is detailed, examining possible predisposing factors and treatment issues.



Efficacy and safety of tamsulosin for the treatment of benign prostatic hyperplasia: a meta analysis.

Comparing three common criteria: international prostate symptom score (IPSS)/Boyarsky symptom score, maximum flow rate (MFR), quality of life (QOL), tamsulosin was better than placebo at improving IPSS and MFR, with no significant difference in the QOL.

Medical Therapy for Benign Prostatic Hyperplasia: A Review of the Literature

This review suggests that both classes of drug offer significant improvement in criteria used to evaluate symptomatic BPH and can be effective whilst being acceptably safe.

Comparison of Tamsulosin and Terazosin in treating benign prostatic hyperplasia:a systematic review

There is evidence showing that tamsulosin seemed to have better efficacy than terazosin in long term therapy at improving QOL, and more high quality trials with large sample and longer follow up are proposed.

Tamsulosin Versus Terazosin for Benign Prostatic Hyperplasia: A Systematic Review

Whether tamsulosin proves more efficacious than terazosin in long term therapy requires confirmation by additional large sample, high quality trials.

Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.

Limited information suggests that treatment with naftopidil provides short-term improvement in urinary symptom-scale scores, QoL (quality of life) score, and urinary symptoms from baseline comparable to low-dose tamsulosin.

Alpha-blocker therapy for benign prostatic hyperplasia: a comparative review.

Until differences in efficacy are demonstrated, the choice of alpha-blocker will depend on tolerance for side effects and convenience of administration, and the effects on symptoms and flow rates are similar.

Evaluation of the Effectiveness of Terazosin, Tamsulosin a nd Finasteride for Benign Prostatic Hyperplasia

It is suggested that tamsulosin alone sould be used for the treatment of BPH and the combination needs to be identifie d by better evidence, as there is not enough evidence to show which one is the best among the three drugs.

A systematic review of tamsulosin compared with terazosin for patient with benign pros-tatic hyperplasia

Current clinical studies might confirm that tsmsulosin is super to terazesin for patients with benign prostatic hyperplasia in terms of improving IPSS, dizzi-ness, postural hypotension, thirsty, and there was no significant difference between the two groups with regard to QOL, Qmax,Qave,residual urine volume.